Updates and Statements

12.09.2020

Statement on EMA Cyberattack

12.01.2020

Pfizer and BioNTech Submitted Application for Conditional Marketing Authorization for COVID-19 Vaccine to the EMA

07.22.2020

Pfizer Shares Pre-Clinical Data Updates on COVID-19 Antiviral Research Program

06.29.2020

Pfizer Statement on Facebook Advertising Boycott

06.23.2020

NEW DATA ON THE BURDEN OF EMERGING S. PNEUMONIAE SEROTYPES PUBLISHED IN ISPPD 2020 ONLINE DIGITAL LIBRARY

06.16.2020

Merck and Pfizer’s SGLT2 Inhibitor STEGLATROTM (ertugliflozin) Meets Primary Endpoint in VERTIS CV Trial for Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease

06.05.2020

Ready to Respond: Pfizer’s Zithromax® Program & Covid-19

06.01.2020

Annaliesa Anderson, Ph.D., Will Lead Pfizer’s Vaccine Research & Development 

05.01.2020

Pfizer Receives Positive CHMP Opinion for DAURISMOTM (glasdegib)for Certain Adult Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

03.02.2020

Pfizer Provides Comment on COVID-19 White House Meeting

01.23.2020

Pfizer Brings Three New Biosimilars to U.S. Patients at Substantial Discounts

11.15.2019

Pfizer Announces CHMP Opinion for XELJANZ® (tofacitinib) in the European Union Related to Ongoing Review of the Product